| Wang, Chunyan |
NCT06155396: A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 116 | RoW | Disitamab Vedotin, Disitamab Vedotin （RC48-ADC), Zimberelimab | RemeGen Co., Ltd. | Cervical Cancer | 06/27 | 12/27 | | |
TQB2450-II-14, NCT05481645: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. |
|
|
| Recruiting | 2 | 79 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer, Sarcoma of Uterus | 06/24 | 12/24 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Terminated | 1/2 | 23 | RoW | TQ-B3525 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 11/23 | 11/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
| Recruiting | N/A | 10000 | RoW | Installation or registration of smartphone application | Chinese Alliance Against Lung Cancer | Solitary Pulmonary Nodule | 10/25 | 10/25 | | |
